A

Anebulo Pharmaceuticals
D

ANEB

1.43000
USD
-0.17
(-10.63%)
Market Closed
Volume
200
EPS
-0
Div Yield
-
P/E
-5
Market Cap
37,084,500
News

Title: Anebulo Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.